Generation Bio Co
Company Profile
Business description
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Contact
301 Binney Street
CambridgeMA02142
USAT: +1 617 655-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
115
Stocks News & Analysis
stocks
The long-term case for compounders
stocks
Record production for Woodside
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,100.50 | 10.50 | -0.12% |
| CAC 40 | 8,126.53 | 55.17 | 0.68% |
| DAX 40 | 24,538.81 | 229.35 | 0.94% |
| Dow JONES (US) | 48,892.47 | 179.09 | -0.36% |
| FTSE 100 | 10,223.54 | 51.78 | 0.51% |
| HKSE | 27,387.11 | 580.98 | -2.08% |
| NASDAQ | 23,461.82 | 223.30 | -0.94% |
| Nikkei 225 | 53,956.50 | 633.65 | 1.19% |
| NZX 50 Index | 13,424.78 | 1.60 | 0.01% |
| S&P 500 | 6,939.03 | 29.98 | -0.43% |
| S&P/ASX 200 | 8,808.40 | 12.70 | -0.14% |
| SSE Composite Index | 4,117.95 | 0.00 | 0.00% |